1426055-14-2

1426055-14-2 structure

Name: Lanadelumab
Chemical Name: Lanadelumab
CAS Number: 1426055-14-2
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Metabolic Enzyme/Protease Ser/Thr Protease
Create Date: 2022-08-04 17:44:04
Modify Date: 2024-01-04 20:31:11
Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema[1][2].

Name	Lanadelumab

Description	Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Ser/Thr Protease Research Areas >> Inflammation/Immunology
In Vitro	Lanadelumab (0-1000 nM) inhibits pKal proteolytic activity of single-chain HMWK (its endogenous protein substrate), and addition of Lanadelumab to pKal samples in vitro preventes the proteolysis of HMWK and the consequent release of bradykinin with an IC50 value of 1.3 nM[2].
In Vivo	Lanadelumab (20 mg/kg; i.v. or s.c.) shows a long half-life of about 12.5 days and blocks high molecular weight kininogen proteolysis in activated plasma in a dose- and time-dependent manner in cynomolgus monkeys[2]. Lanadelumab (1, 30 mg/kg; s.c.) inhibits carrageenan-induced paw edema in the Male Sprague-Dawley rats [2].
References	[1]. Riedl MA, et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy. 2020 Nov;75(11):2879-2887. [2]. Kenniston JA, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014 Aug 22;289(34):23596-608.

No Any Chemical & Physical Properties